{"news_desk": "Business", "print_page": "3", "section_name": "Business Day", "subsection_name": "DealBook", "byline": {"original": "By PETER EAVIS", "person": [{"rank": 1, "role": "reported", "firstname": "Peter", "organization": "", "lastname": "EAVIS"}]}, "abstract": "Admission by Valeant Pharmaceuticals that it improperly booked $58 million in revenue, while minor in comparison to company's overall financial scope, could lend credence to longstanding accusations of flawed accounting practices; company has acknowledged that other lapses may require review. ", "type_of_material": "News", "word_count": "1208", "lead_paragraph": "Investors have other reasons to remain concerned about the accuracy of the company\u2019s financial statements.", "pub_date": "2016-03-29T00:00:00Z", "document_type": "article", "slideshow_credits": null, "headline": {"main": "Valeant\u2019s Accounting Error a Warning Sign of Bigger Problems", "print_headline": "Valeant\u2019s Small Accounting Error Is a Warning Sign to Investors of Bigger Problems"}, "snippet": "Investors have other reasons to remain concerned about the accuracy of the company\u2019s financial statements.", "multimedia": [{"height": 126, "url": "images/2016/03/29/business/29db-valeantaccounting/29db-valeantaccounting-thumbWide.jpg", "legacy": {"widewidth": "190", "wideheight": "126", "wide": "images/2016/03/29/business/29db-valeantaccounting/29db-valeantaccounting-thumbWide.jpg"}, "type": "image", "width": 190, "subtype": "wide"}, {"height": 400, "url": "images/2016/03/29/business/29db-valeantaccounting/29db-valeantaccounting-articleLarge.jpg", "legacy": {"xlargewidth": "600", "xlargeheight": "400", "xlarge": "images/2016/03/29/business/29db-valeantaccounting/29db-valeantaccounting-articleLarge.jpg"}, "type": "image", "width": 600, "subtype": "xlarge"}, {"height": 75, "url": "images/2016/03/29/business/29db-valeantaccounting/29db-valeantaccounting-thumbStandard.jpg", "legacy": {"thumbnailwidth": "75", "thumbnail": "images/2016/03/29/business/29db-valeantaccounting/29db-valeantaccounting-thumbStandard.jpg", "thumbnailheight": "75"}, "type": "image", "width": 75, "subtype": "thumbnail"}], "web_url": "http://www.nytimes.com/2016/03/29/business/dealbook/valeants-accounting-error-a-warning-sign-of-bigger-problems.html", "keywords": [{"rank": "1", "is_major": "Y", "value": "Valeant Pharmaceuticals International Inc", "name": "organizations"}, {"rank": "2", "is_major": "N", "value": "Accounting and Accountants", "name": "subject"}, {"rank": "3", "is_major": "N", "value": "Mergers, Acquisitions and Divestitures", "name": "subject"}, {"rank": "4", "is_major": "N", "value": "Philidor Rx Services LLC", "name": "organizations"}, {"rank": "5", "is_major": "N", "value": "Bausch & Lomb Incorporated", "name": "organizations"}, {"rank": "6", "is_major": "N", "value": "Pearson, John Michael (1959- )", "name": "persons"}, {"rank": "7", "is_major": "N", "value": "Drugs (Pharmaceuticals)", "name": "subject"}], "blog": [], "_id": "56f99b2238f0d874a87cb052", "source": "The New York Times"}